Condition: Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE) · Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease · Autoimmune Encephalitis · Sponsor: Arialys Australia Pty Ltd
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR autoantibody-associated psychiatric disease
This description comes directly from the study's public registry record.
April Purcell · 1-619-865-6365 · apurcell@arialysrx.com
Mari Maurer · 1-415-827-6713 · mmaurer@arialysrx.com
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07093333